gelatin-doxorubicin

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

1.	Hsieh, Hao-Ying: 1 article (01/2016)
2.	Lu, Kun-Ying: 1 article (01/2016)
3.	Mi, Fwu-Long: 1 article (01/2016)
4.	Tsai, Li-Chu: 1 article (01/2016)
5.	Wang, Sin-Yu: 1 article (01/2016)
6.	Cammarata, Christopher R: 1 article (08/2013)
7.	Ofner, Clyde M: 1 article (08/2013)
8.	Park, Hyun Joo: 1 article (08/2013)
9.	Rhodes, Brian T: 1 article (08/2013)
10.	Wu, Darren C: 1 article (08/2013)

1.	Prostatic Neoplasms (Prostate Cancer) 01/01/2016 - "EGCG/gelatin-doxorubicin gold nanoparticles enhance therapeutic efficacy of doxorubicin for prostate cancer treatment." 01/01/2016 - "Development of epigallocatechin gallate (EGCG) and gelatin-doxorubicin conjugate (GLT-DOX)-coated gold nanoparticles (DOX-GLT/EGCG AuNPs) for fluorescence imaging and inhibition of prostate cancer cell growth. "
2.	Neoplasms (Cancer) 12/01/2006 - "Anti-tumor and anti-metastatic effects of gelatin-doxorubicin and PEGylated gelatin-doxorubicin nanoparticles in SCC7 bearing mice." 12/01/2006 - "Gelatin-doxorubicin (GD) and PEGylated gelatin-doxorubicin (PGD) nanoparticles were designed and their feasibilities as an anti-cancer drug were evaluated. "
3.	Lymphoma (Lymphomas) 08/01/2013 - "The gelatin-doxorubicin conjugate (G-DOX) was evaluated for hydrazide and DOX content by spectrophotometry, molecular weight by HPLC-SEC, in vitro DOX release at various pH, and cell growth inhibition using EL4 mouse lymphoma and PC3 human prostate cells. "

1.	Gold
2.	Doxorubicin (Adriamycin)
3.	Prostaglandins D
4.	Hydrazines
5.	epigallocatechin gallate (epigallocatechin-3-gallate)